In 3 pivotal trials, adult patients with moderate-to-severe atopic dermatitis not adequately controlled with topical treatments were randomized to DUPIXENT 300 mg Q2W or placebo. In Trial 3, concomitant TCS was used. Other endpoints measured included the proportion of subjects with EASI-75 (improvement of ≥75% in Eczema Area and Severity Index [EASI] score from baseline) and the mean improvement in EASI score from baseline. EASI is a composite score (ranging from 0 to 72) based on the extent and severity of the atopic dermatitis lesions.1-4
For all patients, moderate-to-severe atopic dermatitis was treated with concomitant TCS. Results are presented at 16 and 52 weeks.
EASI, Eczema Area and Severity Index; TCS, topical corticosteroids.